LENSAR, Inc.

What they do

LENSAR designs, develops, and markets the LENSAR Laser System (LLS) and the ALLY Robotic Cataract Laser System, along with disposable patient interface device (PID) kits and per-procedure licenses. It sells systems directly in the U.S. and through distributors in Europe, Asia, and other international markets, and manufactures at a facility in Orlando, Florida.

Revenue drivers

• Procedure revenue — Per-procedure license fees and PID kit sales; Q2 2026 revenue of $10.2M, up 23% year-over-year, representing 62% of total Q2 revenue.
• Lease revenue — Recurring lease revenue from systems under lease agreements; Q2 2026 revenue of $1.8M, up 8% year-over-year, about 11% of total revenue.
• Service revenue — Service contracts and maintenance on installed systems; Q2 2026 revenue of $1.7M, up 22% year-over-year, about 10% of total revenue.
• System sales — Upfront sales of LLS and ALLY systems; Q2 2026 revenue of $2.8M, up 9% year-over-year, representing 17% of total revenue.

Recent performance

For Q2 2026, total revenue was $16.5M, up 18% from $13.9M in Q2 2025, and the company reported net income of $3.5M versus a net loss of $1.8M a year earlier. Recurring revenue rose 20% to $13.7M, and procedure volume increased 13% to 58,682. The installed base grew to 445 total laser systems, with ALLY placements growing 30% to 215 systems. For fiscal 2025, revenue was $51.7M with a net loss of $34.3M, and as of June 30, 2026, cash was $13.6M with shareholder equity of $14.9M.

Strategy

LENSAR is focused on expanding its ALLY System adoption, which received FDA clearance in June 2022 and EU MDR certification in August 2024. It is building a direct sales force in the U.S. and using distributors in Europe, Asia, and other markets, with a commercial team of about 70 professionals as of June 30, 2026. The company emphasizes a recurring revenue model via procedure licenses and subscription packages with minimum monthly obligations. It continues to pursue additional regulatory clearances for ALLY in other countries and invests in innovation to improve visual outcomes and operational efficiency.

Risks

• Regulatory approval dependence — Future revenue depends on obtaining and maintaining regulatory clearances for the ALLY System in various jurisdictions, and delays or denials could hurt growth.
• Supply chain concentration — The company relies on single-source suppliers for many components, and disruptions could impact manufacturing and delivery.
• Continued losses and cash burn — LENSAR has incurred net losses every year from 2021 through 2025, with 2025 net loss of $34.3M and negative operating cash flow of $14.8M, requiring ongoing capital.
• Customer adoption risk — Sales depend on surgeons' willingness to adopt new laser technology and on procedure volume growth, which can be affected by economic and market conditions.

Outlook

Management highlighted a backlog of 13 ALLY Systems pending installation as of June 30, 2026, and expects continued growth from increasing installed base and recurring revenue. The company expressed confidence in the trajectory of the business, citing strong second quarter results and sustained demand for ALLY. No specific full-year guidance was provided in the earnings release.